
HROW Stock Forecast & Price Target
HROW Analyst Ratings
Bulls say
Harrow is a company with a strong foundation in delivering pharmaceutical products for eye care, with established relationships and a new drug, MELT, that has potential for cross-selling and growth. While regulatory challenges and potential changes in expenses and regulations may impact financial projections, the company is still expected to see significant growth in the near future with the adoption of their current products, such as IHEEZO, and the submission of a New Drug Application for MELT-300, which could replace opioid-based sedation in cataract surgeries.
Bears say
Harrow is a company that specializes in the development and commercialization of ophthalmic pharmaceutical products, particularly for the treatment of various eye conditions. Despite recent profitability, the company has a history of operating losses and may struggle to sustain profitability in the future due to limited capital. Furthermore, the company faces tough competition in the eye care market and may need to raise additional funds to support its operations and launch new products. Given the challenges the company faces, it is likely to have a negative impact on its stock performance in the long run.
This aggregate rating is based on analysts' research of Harrow Health Inc and is not a guaranteed prediction by Public.com or investment advice.
HROW Analyst Forecast & Price Prediction
Start investing in HROW
Order type
Buy in
Order amount
Est. shares
0 shares